Mission & Vision
Cardiac failure is the No. 1 cause of death worldwide. The most frequent single acute cause is the heart attack. One in ten patients then experience life-threatening cardiogenic shock (acute cardiovascular failure), which is unforeseeable and can occur anywhere. The application over decades of heart-lung machines (HLMs) in cardiac surgery has proved that it is possible to replace circulation with a machine. Conventional HLMs are large, heavy and complex, and that is why they are virtually useless in practice for the emergency treatment of these patients. With the new, portable and easily operated LIFEBRIDGE B2T® ("Bridge-to-Therapy"), LIFEBRIDGE Medizintechnik AG for the first time opens up to all doctors involved in the treatment of this condition the possibility of replacing patients’ circulation immediately at any location, thereby saving them from death through cardiogenic shock.
LIFEBRIDGE Medizintechnik AG has set itself the goal of providing mechanical cardiovascular support to significantly more patients than are receiving such support today in the decisive moments of their lives. This challenge has been taken up by experienced entrepreneurs, engineers, physicians and investors in order, through their know-how and commitment, to set new technological standards in invasive emergency medicine. Acknowledged experts from the worlds of medicine, science and industry are making their crucial contributions with conviction to close life-threatening gaps in the chain of medical care.
A highly distinguished team and a sound technological lead characterize LIFEBRIDGE Medizintechnik AG as an innovative company and world leader in the supply of life-preserving systems for acute medical care. This unique position offers enormous potential for the economic development of the company and the greatest opportunities for employees and shareholders in a lucrative and constantly growing market.
